You are here

Approvals, Launches, and New Indications

First medication for both relapsing and primary progressive forms of the disease
PARP inhibitor improves progression-free survival
The human anti-PD-L1 antibody is the first therapy for this rare skin cancer
Ocrevus and Dupixent set to make a splash
Monoamine oxidase B inhibitor approved as add-on to levodopa
Treatment reduces risk of disease progression or death
First agency-cleared treatment for this condition
Once-daily treatment combines SGLT-2 inhibitor and DPP-4 inhibitor
The drug is the first and only oral medication for this debilitating condition